Clinical trials and real world-experience of anti-PD-1/PD-L1 CPI use in sarcomas have shown that a subset of UPS and DDLPS patients derive clinical benefits from this class of drugs37,38,49–51. This evidence concerns the gene CD274 and undifferentiated pleomorphic sarcoma.